Hedge funds and other institutional investors own 74.03% of the company's stock. Suntrust Banks Inc. reduced its stake in shares of Gilead Sciences, Inc. The stock increased 0.89% or $0.09 on July 17, reaching $10.21. About 151,929 …
Gilead Sciences, Inc. (NASDAQ:GILD). Rhenman & Partners Asset Management Ab bought 50,000 shares in quarter …
"The near term upside for Gilead’s stock from this transaction might not be as …
Maxim Group reaffirmed a "hold" rating on shares of Gilead Sciences in a research report on Friday, April 21st. The firm has "Neutral" rating given on Monday, January 18 by Bank of America. On Friday, July 24 the stock rating was …
Buying Incyte may not do as much for Gilead’s stock price near term as Vertex, since Incyte’s big revenue growth begins in 2022, but they see a Gilead-Incyte …
Holowesko Partners Ltd acquired 526,000 shares as Gilead Sciences Inc (GILD)'s stock declined 8.05%. The Rosenblum Silverman Sutton S F Inc holds 56,586 shares with $4.05M value, down from 65,122 last quarter. HPM Partners LLC …
And when governments are your market … well, that’s a big market. In any case, Gilead did not develop the IP itself, it was acquired by taking over a smaller …
Gilead Sciences, Inc. (NASDAQ:GILD) stock has been caught in a funk. I have expressed my views on this investment on multiple occasions, and each time, I have come to the same bearish conclusion about Gilead stock. The purpose of …
For the past 12 months Gilead Sciences, Inc. (NASDAQ:GILD) could have served as the poster-child for a falling knife to avoid. Many tried to catch it and lost a few fingers doing it. Calling a bottom in the stock was a fool’s errand… Until now.
Epclusa should improve sales in HCV. It is coming in cheaper than Harvoni and can be used on both genotype 2 and 3 patients. Expect to see Gilead's TAF range of HIV treatments continue to increase its sales numbers. Technically …